ArticleJournal of translational medicine2026
Heterogeneity characterization and therapeutic marker discovery of endometrial carcinoma using GeoMXT™ digital spatial profiling.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study aimed to explore the intra- and inter-tumoral heterogeneity, gene expression profiles, tumor microenvironment (TME) alterations and the potential of therapeutic marker discovery in endometrial cancer (EC).
methodsDigital spatial profiling (DSP) technology was used to quantify transcript abundance in distinct spatial regions of EC tissues from 4 patients. The differences among the regions were explored using bioinformatics analysis, and the mechanisms contributing to these differences were preliminarily explored using in vitro experiments.
resultsWe focused on 23 regions of interest (ROI), including 8 from normal cells, 10 from tumor cells (TC), 1 from stroma adjacent to normal cells and 4 from regions that encompassed the former three types of cells. Gene set variation analysis with 8 gene sets associated with EC revealed significant heterogeneity both within and between tumors. We estimated the abundance of immune cells in each region and found that significant disparities were observed in both the abundance and proportional representation of immune cells across all 23 ROIs. ATF5, identified as a key transcription factor, and its functionally linked target genes STMN1, CENPF, and TROAP were significantly overexpressed in TC, which was confirmed by RT-qPCR and external database analyses. Correlation analysis combined with functional assays demonstrated that ATF5 directly activates STMN1 transcription by binding to its promoter. ATF5 or STMN1 knockdown induced G2/M arrest and suppressed proliferation. Importantly, STMN1 re-expression rescued the proliferative and clonogenic defects caused by ATF5 knockdown.
conclusionOur exploratory study provides preliminary evidence of significant intra- and inter-tumoral heterogeneity in the TME and signaling pathways in EC using DSP technology. Genes such as ATF5, STMN1, CENPF, and TROAP, particularly the ATF5-STMN1 axis as a potential oncogenic pathway, may contribute to this heterogeneity and warrant further investigation as potential biomarkers and therapeutic targets in larger validation cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.